Bristol Myers Squibb Company (NYSE: BMY) has reported positive topline results from its pivotal Phase 3 ALOFT-IPF trial, demonstrating that investigational admilparant at 60 mg twice daily significantly slowed the decline in lung function among adults with idiopathic pulmonary fibrosis. Announced on October 12, 2026, the approximately 1,255-patient study met its primary endpoint for the lower dose after 52 weeks of treatment, while the higher 120 mg twice-daily dose showed a numerical benefit that did not achieve statistical significance.
The findings represent an important clinical milestone for admilparant, previously known as BMS-986278, an oral lysophosphatidic acid receptor 1 antagonist being developed as a potential first-in-class treatment for pulmonary fibrosis. However, the difference between the two dose groups introduces a consequential question about the relationship between drug exposure, antifibrotic activity and the treatment effect observed in patients. Bristol Myers Squibb has not yet disclosed the absolute lung-function differences, confidence intervals or p-values from the Phase 3 trial, limiting assessment of the magnitude and consistency of the result.
The company reported that admilparant was generally well tolerated at both doses, with adverse-event-related discontinuation rates described as low and comparable with placebo. It intends to complete a comprehensive assessment of the dataset and engage regulatory authorities regarding planned submissions, with detailed findings expected at a future medical meeting. Admilparant remains investigational and is not approved for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
The development comes as treatment options for pulmonary fibrosis have expanded following the United States Food and Drug Administration’s approval of Boehringer Ingelheim’s Jascayd (nerandomilast) in October 2025. Consequently, Bristol Myers Squibb would be entering a market that now includes three established oral antifibrotic medicines, rather than addressing a therapeutic area without recent innovation. Its competitive opportunity will depend on whether targeting the LPA1 pathway provides a clinically meaningful and tolerable option alongside existing treatments.
What do the ALOFT-IPF Phase 3 results reveal about admilparant’s effect on lung function?
ALOFT-IPF, registered as NCT06003426, is a global, multicentre, randomized, double-blind, placebo-controlled Phase 3 trial evaluating two admilparant doses in adults aged 40 years and older with idiopathic pulmonary fibrosis. Approximately 1,255 participants were assigned in a 1:1:1 ratio to receive 60 mg twice daily, 120 mg twice daily or placebo for at least 52 weeks. The study permitted patients to participate with or without stable background antifibrotic treatment, allowing evaluation within a population reflecting different established treatment approaches.
The primary endpoint was absolute change from baseline in forced vital capacity, measured in millilitres, at Week 52. Forced vital capacity, or FVC, measures the amount of air a person can forcibly exhale after taking a full breath and is widely used to monitor pulmonary function in patients with fibrotic lung disease. A slower decline in FVC provides evidence that a treatment can reduce the rate of lung-function deterioration, although it does not directly demonstrate improved survival, symptom relief or reversal of established lung scarring.
Bristol Myers Squibb reported that the 60 mg dose achieved a statistically significant treatment difference against placebo. The 120 mg group also showed a numerical reduction in lung-function decline, but the difference did not meet the trial’s statistical significance threshold. This means the study achieved its primary efficacy objective for one tested dose, while the evidence for the higher dose remains less conclusive.
The announcement did not identify how many millilitres of FVC were preserved with either dose, how much lung function declined in the placebo group or the confidence intervals surrounding the treatment estimates. It also did not provide detailed subgroup outcomes according to background antifibrotic treatment. These omissions prevent an independent assessment of the absolute clinical benefit, even though the reported primary endpoint result establishes statistical superiority for the 60 mg regimen.
Why did the 120 mg admilparant dose miss statistical significance when 60 mg succeeded?
The differing results between the two doses are arguably the most important unresolved question in the ALOFT-IPF announcement. Higher exposure to a pharmacologically active compound does not necessarily produce greater clinical benefit, particularly when receptor effects, biological feedback and treatment tolerability influence outcomes. However, the current disclosure does not provide sufficient evidence to explain why the 120 mg dose failed to achieve statistical significance.
Several possibilities require examination, including the magnitude of the observed treatment difference, variability in FVC measurements, treatment adherence, dose interruptions and the characteristics of patients assigned to each group. Statistical uncertainty can also produce different significance outcomes between treatment arms without proving that the lower dose is more effective. A direct comparison between the 60 mg and 120 mg groups would be necessary before concluding that the lower dose provides superior efficacy.
The distinction matters for eventual regulatory dose selection. Regulators will need to assess whether the 60 mg response is sufficiently robust, whether findings are consistent across important subgroups and whether the relationship between exposure and efficacy supports the proposed regimen. The fact that the higher dose missed its statistical objective does not invalidate the positive result at 60 mg, but it makes the complete dose-response analysis particularly important.
Bristol Myers Squibb has not indicated that the 120 mg result arose from increased toxicity, excessive treatment discontinuations or a specific biological limitation. The company instead described both doses as generally well tolerated and said it would evaluate the complete dataset before discussions with health authorities. Until those analyses become available, any explanation for the higher-dose result would remain speculative.
How does admilparant’s LPA1 mechanism differ from existing antifibrotic medicines?
Admilparant is designed to block lysophosphatidic acid receptor 1, commonly abbreviated LPA1, a signalling receptor involved in processes associated with pulmonary fibrosis. Lysophosphatidic acid signalling can contribute to epithelial injury responses, vascular permeability, inflammatory activity and fibroblast behaviour. These mechanisms are relevant because persistent tissue injury and abnormal repair processes contribute to the accumulation of fibrotic tissue within the lungs.
The investigational medicine aims to interfere with several biological processes associated with fibrogenesis rather than target a single visible feature of established scarring. Bristol Myers Squibb has described the approach as addressing abnormal epithelial repair, inflammation and vascular leakage, and fibroblast activation. These proposed mechanistic effects are supported by the biological rationale for LPA1 inhibition, but the Phase 3 topline announcement does not establish that admilparant reverses existing fibrosis.
Current oral treatment options act through different pathways. Boehringer Ingelheim’s Ofev (nintedanib) inhibits multiple tyrosine kinases involved in fibrotic signalling, while Roche’s Esbriet (pirfenidone) has antifibrotic and anti-inflammatory properties. Jascayd (nerandomilast), also developed by Boehringer Ingelheim, selectively inhibits phosphodiesterase 4B and was approved in the United States for idiopathic pulmonary fibrosis in October 2025.
That evolving treatment landscape makes admilparant’s distinct mechanism commercially relevant. If approved, the drug could provide physicians with another way to slow lung-function deterioration, potentially benefiting patients who cannot tolerate particular existing medicines or who require additional treatment options. However, the current ALOFT-IPF results do not demonstrate superiority over nintedanib, pirfenidone or nerandomilast because the randomized comparison was against placebo rather than an active antifibrotic comparator.
How do the latest Phase 3 findings compare with admilparant’s published Phase 2 evidence?
The Phase 3 success builds on an earlier randomized Phase 2 trial that evaluated admilparant over 26 weeks in separate idiopathic pulmonary fibrosis and progressive pulmonary fibrosis cohorts. The study enrolled 278 participants with idiopathic pulmonary fibrosis and 125 with progressive pulmonary fibrosis, evaluating 30 mg and 60 mg twice-daily doses against placebo. Its findings were subsequently published in the American Journal of Respiratory and Critical Care Medicine.
In the idiopathic pulmonary fibrosis cohort, the 60 mg group demonstrated a slower decline in percentage-predicted FVC than placebo. Under the treatment-policy analysis, which incorporated available observations regardless of dose reduction, the decline was 1.2 percentage points with admilparant compared with 2.7 percentage points for placebo. The estimated treatment difference was 1.4 percentage points, corresponding to a 54% relative reduction in the rate of decline, although the 95% confidence interval ranged from negative 0.1 to positive 3.0 percentage points.
A separate prespecified while-on-treatment analysis produced an estimated 62% relative reduction, with a treatment difference of 1.8 percentage points and a 95% confidence interval of 0.2 to 3.4 percentage points. This analysis excluded observations following dose reduction, explaining why its efficacy estimate differed from the treatment-policy result. The frequently cited 62% figure therefore describes a particular analysis of relative lung-function decline over 26 weeks, not a 62% improvement in breathing capacity or a reduction in mortality.
The Phase 3 programme was designed to test the therapeutic hypothesis in a substantially larger population over a longer period. Its positive 60 mg result strengthens the evidence that LPA1 inhibition can influence lung-function deterioration in idiopathic pulmonary fibrosis. Nevertheless, the Phase 2 relative treatment effects should not be applied to the Phase 3 findings, which use an absolute FVC endpoint and have not yet been disclosed quantitatively.
What do the reported safety findings establish about admilparant’s tolerability?
Bristol Myers Squibb characterised admilparant’s Phase 3 safety profile as favourable, reporting that adverse-event-related discontinuations were low and similar between the active-treatment groups and placebo. This is potentially relevant in idiopathic pulmonary fibrosis, where patients may require prolonged treatment and where tolerability problems can interfere with sustained medication use. However, the disclosure provides an overall safety characterization rather than detailed comparative safety data.
The company did not publish treatment-emergent adverse-event rates, serious adverse-event frequencies, deaths, laboratory abnormalities or organ-specific safety findings from ALOFT-IPF. Without those numbers, it is not possible to determine whether particular adverse events were more frequent at 120 mg, whether there were dose-related laboratory changes or whether important differences emerged within patient subgroups. Low discontinuation rates alone do not establish that a medicine has a negligible adverse-effect burden.
Long-term tolerability is particularly relevant when comparing new antifibrotic treatment options. Existing medicines can be associated with gastrointestinal symptoms and other adverse reactions that require monitoring or changes in treatment. A medicine with a different mechanism could offer a useful alternative, but the presence or absence of overlapping toxicities must be established from clinical evidence rather than inferred from receptor selectivity.
The full Phase 3 safety assessment will therefore be central to the regulatory review. Physicians and regulators will need to examine adverse-event severity, treatment interruptions, dose reductions, laboratory findings and the safety profile among patients also receiving background antifibrotic treatment. Bristol Myers Squibb’s statement supports an encouraging preliminary interpretation, but it does not replace a detailed safety analysis.
Could admilparant offer additional benefit alongside established IPF treatments?
One commercially important feature of the ALOFT programme is that participation was permitted with or without stable background antifibrotic therapy. This allows the investigational treatment to be assessed within a wider clinical setting than a trial restricted exclusively to untreated patients. However, the company has not yet disclosed Phase 3 efficacy results separately for patients receiving background medicines and those not receiving them.
The distinction is important because a new medicine could potentially be used as an alternative treatment, an additional treatment or both, depending on its approved label and supporting evidence. Demonstrating benefit in patients already receiving antifibrotic medicines would be particularly relevant to combination-treatment strategies. Yet the overall positive primary endpoint does not automatically establish that the incremental benefit was statistically significant within every background-treatment subgroup.
The Phase 2 programme reported treatment effects that appeared generally consistent regardless of whether participants received background antifibrotic medicines. Those findings helped support continued clinical development, but they were generated in a smaller population over 26 weeks. Larger Phase 3 subgroup analyses will be needed to better understand the consistency of benefit and tolerability when admilparant is administered alongside existing treatments.
The commercial implications could be substantial if the final evidence supports more than one practical treatment setting. Combination use might expand the population considered for treatment, while an alternative monotherapy option could address patients who discontinue existing medicines because of tolerability concerns. Both possibilities remain dependent on the complete clinical dataset, regulatory evaluation and eventual prescribing information.
Why is the ALOFT-PPF trial an important second opportunity for Bristol Myers Squibb?
Beyond idiopathic pulmonary fibrosis, Bristol Myers Squibb is evaluating admilparant in progressive pulmonary fibrosis through a separate Phase 3 study, ALOFT-PPF. The trial enrolled approximately 1,057 adults aged 21 years and older with progressive pulmonary fibrosis, with or without stable background antifibrotic therapy. The company expects topline results in early 2027.
Progressive pulmonary fibrosis describes a pattern of worsening fibrosis occurring in interstitial lung diseases other than idiopathic pulmonary fibrosis. These conditions can include connective tissue disease-associated interstitial lung disease and other disorders where fibrosis progresses despite appropriate management. Although the clinical course and causes differ, progressive loss of lung function creates a related therapeutic challenge.
The ALOFT-PPF trial uses the same broad randomized, double-blind, placebo-controlled framework and evaluates 60 mg and 120 mg twice-daily admilparant against placebo. Its primary endpoint is absolute change in FVC from baseline at Week 52. The study is distinct from ALOFT-IPF, and success in idiopathic pulmonary fibrosis does not establish efficacy in the broader progressive pulmonary fibrosis population.
The earlier Phase 2 progressive pulmonary fibrosis cohort demonstrated an estimated 69% relative reduction in lung-function decline with 60 mg twice-daily admilparant compared with placebo in the company’s reported analysis. That provides a rationale for the ongoing Phase 3 study, but the magnitude of benefit cannot be assumed to recur. The early-2027 readout will therefore be an independent test of whether the LPA1 mechanism has therapeutic activity across different fibrotic lung diseases.
The competitive environment has also changed in this indication. Nerandomilast received a separate United States approval for progressive pulmonary fibrosis in December 2025, adding another treatment option beyond previously established therapy. An eventual admilparant launch would consequently require clear evidence of clinical benefit and an acceptable safety profile in both disease populations.
What does the Phase 3 result mean for Bristol Myers Squibb’s pipeline and investor sentiment?
The positive ALOFT-IPF result arrives as Bristol Myers Squibb seeks to expand its growth portfolio ahead of important patent-related pressures affecting established medicines. The company reported second-quarter 2026 revenue of approximately $13 billion, an increase of 6% year over year, while its growth portfolio generated $7.6 billion and expanded by 15%. Management increased its full-year revenue guidance in July to approximately $49 billion to $50 billion.
Admilparant represents a potential future product within the company’s expanding immunology and pulmonary disease portfolio. It has not generated commercial revenue, and the October announcement does not provide a filing date, launch forecast or expected sales contribution. Its economic significance will depend on regulatory approval, the final approved indication, treatment adoption and its differentiation from established medicines.
The October 12 market response has been mixed. Bristol Myers Squibb shares initially advanced following the morning disclosures but subsequently reversed direction during early trading, according to market reporting. The company also announced positive Phase 3 results for its investigational radiopharmaceutical RYZ101 on the same day, making it inappropriate to attribute the entire share-price movement to the admilparant result.
Investor concerns appear to centre partly on the absence of quantitative efficacy data and the failure of the higher admilparant dose to achieve statistical significance. At the same time, the lower-dose success provides evidence supporting the drug’s progression toward regulatory discussions. For a company of Bristol Myers Squibb’s scale, the programme offers a potential additional growth driver rather than an immediate change to its financial performance.
What must happen before admilparant can become an approved pulmonary fibrosis treatment?
Bristol Myers Squibb must first complete its analysis of the full ALOFT-IPF dataset, including the absolute treatment effect, statistical confidence intervals and the consistency of results across doses and patient subgroups. Secondary outcomes involving disease progression, exercise capacity and patient-reported symptoms could provide useful information about whether preserved lung function is accompanied by broader clinical benefits. The trial’s planned assessments also include events such as exacerbations, respiratory-related hospitalisations and mortality, although the latest announcement does not report results for these outcomes.
The dose-response question will require particular attention. Regulators will need to determine whether the efficacy and safety evidence adequately supports the proposed 60 mg regimen and whether the 120 mg findings influence interpretation of the overall programme. A statistically significant result at one dose can provide an important basis for regulatory consideration, but the entire evidence package must support the intended treatment recommendation.
Following its evaluation, Bristol Myers Squibb plans to engage health authorities regarding regulatory submissions. The company has not announced that a New Drug Application has been filed or accepted by the United States Food and Drug Administration, and no approval decision date has been established. Detailed presentation of the results at a future medical meeting will provide clinicians and researchers with an opportunity to scrutinise the treatment effect more closely.
The forthcoming ALOFT-PPF readout offers another major milestone. Positive results in progressive pulmonary fibrosis would extend the evidence supporting LPA1 inhibition, while an unsuccessful result would require separate assessment of the mechanism’s activity across different disease populations. The company’s development strategy will therefore be shaped by both the complete idiopathic pulmonary fibrosis findings and the independent progressive pulmonary fibrosis study.
The October 12 announcement establishes an important Phase 3 success for admilparant at 60 mg twice daily, supporting the possibility of a new mechanism-based treatment for idiopathic pulmonary fibrosis. However, the higher-dose result, undisclosed efficacy magnitude and incomplete safety details prevent a definitive assessment of how the medicine would compare with existing options. The next decisive evidence will come from the complete 52-week dataset, particularly whether the preserved lung function is substantial, consistent and accompanied by a safety profile suitable for long-term treatment.
